Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Cibula D, Rob L, Mallmann P, Knapp P, Klat J, Chovanec J, Minar L, Melichar B, Hein A, Kieszko D, Pluta M, Spacek J, Bartos P, Wimberger P, Madry R, Markowska J, Streb J, Valha P, Hassan HIB, Pecen L, Galluzzi L, Fucikova J, Hrnciarova T, Hraska M, Bartunkova J, Spisek R. Cibula D, et al. Among authors: streb j. Gynecol Oncol. 2021 Sep;162(3):652-660. doi: 10.1016/j.ygyno.2021.07.003. Epub 2021 Jul 20. Gynecol Oncol. 2021. PMID: 34294416 Free article. Clinical Trial.
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. N Engl J Med. 2022 Jul 21;387(3):217-226. doi: 10.1056/NEJMoa2202809. N Engl J Med. 2022. PMID: 35857659 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer-A Retrospective Analysis of Consecutive Patients Data.
Buda-Nowak A, Kwinta Ł, Potocki P, Michałowska-Kaczmarczyk A, Słowik A, Konopka K, Streb J, Koniewski M, Wysocki PJ. Buda-Nowak A, et al. Among authors: streb j. J Clin Med. 2023 Feb 8;12(4):1350. doi: 10.3390/jcm12041350. J Clin Med. 2023. PMID: 36835886 Free PMC article.
Dendritic Cells Are Associated with Prognosis and Survival in Breast Cancer.
Szpor J, Streb J, Glajcar A, Frączek P, Winiarska A, Tyrak KE, Basta P, Okoń K, Jach R, Hodorowicz-Zaniewska D. Szpor J, et al. Among authors: streb j. Diagnostics (Basel). 2021 Apr 14;11(4):702. doi: 10.3390/diagnostics11040702. Diagnostics (Basel). 2021. PMID: 33919875 Free PMC article.
Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure.
Sobczuk P, Teterycz P, Lugowska I, Klimczak A, Bylina E, Czarnecka AM, Kosela-Paterczyk H, Osuch C, Streb J, Rutkowski P. Sobczuk P, et al. Among authors: streb j. Oncol Lett. 2019 Sep;18(3):3373-3380. doi: 10.3892/ol.2019.10622. Epub 2019 Jul 16. Oncol Lett. 2019. PMID: 31452817 Free PMC article.
111 results